Hepatitis C virus infection: Establishment of chronicity and liver disease progression

EXCLI Journal

Volumn 13, Issue , 2014, Pages 977-996

  Kwon, Young Chan ^a   Ray, Ratna B ^a   Ray, Ranjit ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAAs; EMT; Fibrosis; HCV; miRNAs; TISCs

Indexed keywords

COMPLEMENT; CYTOKINE; INTERFERON; MICRORNA; VIRUS ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; AUTOPHAGY; CELL LEVEL; CHRONIC LIVER DISEASE; CHRONICITY; CYTOKINE RESPONSE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE ASSOCIATION; HEPATITIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE FUNCTION; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

HEPATITIS C VIRUS;

EID: 84907689570     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (204)

1. Adinolfi LE, Restivo L, Marrone A. The predictive value of steatosis in hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2013;7:205-13.
2. Ait-Goughoulte M, Kanda T, Meyer K, Ryerse JS, Ray R., Ray R. Hepatitis C virus genotype 1a growth and induction of autophagy. J Virol 2008;82:2241-9.
3. Ait-Goughoulte M, Banerjee A, Meyer K, Mazumdar B, Saito K, Ray R. et al. Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokines stimulated acute-phase response. Hepatology 2010;51:1505-13.
4. Akkari L, Gregoire D, Floc’h N, Moreau M, Hernandez C, Simonin Y et al. Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. J Hepatol 2012;57:1021-8.
5. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T et al. Hepatitis C virus-induced cancer stem cell-like signatrues in cell culture and murine tumor xenografts. J Virol 2011;85:12292-303.
6. Alisi A, Giambartolomei S, Cupelli F, Merlo P, Fontemaggi G, Spaziani A et al. Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 2003;22:2573-80.
7. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N, Grantham A et al. CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology 2012;55:354-63.
8. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
9. Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014;95:78-88.
10. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray R., Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008;82:2606-12.
11. Banerjee A, Ray R., Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses 2010a;2:2108-33.
12. Banerjee A, Meyer K, Mazumdar B, Ray R., Ray R. Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol 2010b;84:5936-46.
13. Banerjee A, Mazumdar B, Meyer K, Di Bisceglie AM, Ray R., Ray R. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 2011;85:4157-66.
14. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94:1200-5.
15. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009;83:1299-311.
16. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1.
17. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624-30.
18. Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial mesenchymal transition. PLoS One 2009;4:e4355.
19. Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitizes uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro : implications for trastuzumabbased immunotherapy. Br J Canc 2012;106:1543-50.
20. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray R.. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2012;86:10221-5.
21. Bittar C, Shrivastava S, Bhanja Chowdhury J, Rahal P, Ray RB. Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. PLoS One 2013;8:e62581.
22. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
23. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes 2014;5:52-8.
24. Bose SK, Shrivastava S, Meyer K, Ray R., Ray R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012a;86:6315-22.
25. Bose SK, Meyer K, Di Bisceglie AM, Ray R., Ray R. Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes. J Virol 2012b;86:13621-8.
26. Bose SK, Kim H, Meyer K, Wolin N, Davidson NO, Ray R. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. J Virol 2014;88:4195-203.
27. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002;222:89-94.
28. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
29. Bugiansesi E, Manzini P, D’Antico S, Vanni E, Longo F, Leone N et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004:39;179-87.
30. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 2013;29:243-9.
31. Cho J, Baek W, Yang S, Chang J, Sung YC, Suh M. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochem Biophys Acta 2001;1538:59-66.
32. Choi SH, Hwang SB. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem 2006;281:7468-78.
33. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
34. Chowdhury JB, Kim H, Ray R, Ray R.. Hepatitis C virus NS5A protein modulates IRF-7-mediated interferon-α signaling. J Interferon Cytokine Res 2014;34: 16-21.
35. Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 2003;107:65-73.
36. Conrad KD, Niepmann M. The role of microRNAs in hepatitis C virus RNA replication. Arch Virol 2014; 159:849-62.
37. Conti B, Minutolo A, Arciello M, Balsano C. Are Hedgehog and Wnt/β-catenin pathways involved in hepatitis C virus-mediated EMT? J Hepatol 2013;58: 636-7.
38. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-20.
39. Cullen BR. How do viruses avoid inhibition by endogenous cellular microRNAs? PLoS Pathog 2013a; 9:e1003694.
40. Cullen BR. MicroRNAs as mediators of viral evasion of the immune system. Nat Immunol 2013b;14:205-10. D’Ambrosio R, Colombo M. Safety of direct antiviral agents in real life. Dig Liver Dis 2013;45(Suppl 5):S363-6.
41. Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection. Gastroenterology 2014;147:119-31.
42. Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011;3:2280-300.
43. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009;136:2377-86.
44. Dreux M, Gastaminza P, Wieland SF, Chisari FV. The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci USA 2009;106:14046-51.
45. Ejaz A, Steinmann E, Banki Z, Anggakusuma, Khalid S, Lengauer S et al. Specific acquisition of functional C59 but not CD46 or CD55 by hepatitis C virus. PLOS One 2012;7:e45770.
46. El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to antiviral therapy. World J Gastroenterol 2012;18:212-24.
47. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010;207:2019-31.
48. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum againt the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;24:15394-9.
49. Fattovich G, Stroffolini T, Zagni I, Donato F, Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
50. Finberg RW, White W, Nicholson-Weller A. Decayaccelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992;149:2055-60.
51. Fleming VM, Harcourt G, Barnes E, Klenerman P. Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J Gen Virol 2010; 91:1396-406.
52. Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009;49:839-50.
53. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28:6367-73.
54. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008a;88:125-72.
55. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008b;134:1655-69.
56. Fu BH, Wu ZZ, Qin J. Effects of integrins on laminin chemotaxis by hepatocellular carcinoma cells. Mol Biol Rep 2010;37:1665-70.
57. Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li J. Hepatitis C virus core protein stimulates hepatocyte growth : correlation with upregulation of wnt-1 expression. Hepatology 2005;41:1096-105.
58. Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010;51:378-87.
59. Garaigorta U, Chisari FV, Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009;6:513-22.
60. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-98.
61. Georges PC, Hui JJ, Gombos Z, McCormick ME, Wang AY, Uemura M et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;293:G1147-54.
62. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray R.. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 2000;67:173-8.
63. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C polyprotein cleavage products. J Virol 1993;67:1385-95.
64. Greenbaum LE, Wells RG. The role of stem cells in liver repair and fibrosis. Int J Biochem Cell Biol 2011;43:222-9.
65. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
66. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL et al. Risk factors for hepatocellular carcinoma : synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13.
67. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009;49:1469-82.
68. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 2000; 32:958-61.
69. He QQ, Cheng RX, Sun Y, Feng DY, Chen ZC, Zheng H. Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 cterminal deleted protein. World J Gastroenterol 2003; 9:474-8.
70. He Y, Nakao H, Tan SL, Polyak SJ, Neddermann P, Vijaysri S et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosyphatidylinositol 3-kinase. J Virol 2002;76:9207-17.
71. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999;73: 8469-75.
72. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-56.
73. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014;426; 1198-209.
74. Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 2000;49:103-16.
75. Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M et al. Hepatocellular carcinoma in patients with nonalcoholice fatty liver disease : helical CT and MR imaging findings with clinical pathologic comparison. Radiology 2007:243;422-30.
76. Iqbal J, McRae S, Mai T, Banaudha K, Sarkar-Dutta M, Waris G. Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS One 2014; 9:87464.
77. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110:341-50.
78. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94.
79. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309:1577-81.
80. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, Kneteman N et al. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLOS Pathog 2009;5: e1000291.
81. Jung Y, Brown KD, Witek RP, Omenetti A, Yang L, Vandongen M et al. Accumulation of hedgehogresponsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology 2008;134:1532-43.
82. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
83. Kanda T, Steele R, Ray R, Ray R.. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol 2008;82:11066-72.
84. Kang JI, Kwon SN, Park SH, Kim YK, Choi SY, Kim JP et al. PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control. Virus Res 2009a;142:51-6.
85. Kang SM, Kim SJ, Kim JH, Lee W, Kim GW, Lee KH et al. Interaction of hepatitis C virus core protein with Hsp60 triggers the production of reactive oxygen species and enhances TNF-alpha-mediated apoptosis. Cancer Lett 2009b;279:230-7.
86. Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastases? Hepatology 2011;54:707-13.
87. Kang W, Sung PS, Park SH, Yoon S, Chang DY, Kim S et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+T cell effector functions. Gastroenterology 2014;146:1351-60.
88. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-8.
89. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008;38:1-26.
90. Kato N, Lan KH, Ono-Nita SK, Shiratori Y, Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 1997;71: 8856-9.
91. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009;44:1190-4.
92. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006;118:127-36.
93. Kim H, Mazumdar B, Bose SK, Meyer K, Di Bisceglie AM, Hoft DF et al. Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface. J Virol 2012;86; 9919-28.
94. Kim H, Meyer K, Di Bisceglie AM, Ray R. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858-67.
95. Kim H, Bose SK, Meyer K, Ray R. Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. J Virol 2014;88:2564-71.
96. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virusdiabetes association. Am J Gastroenterol 2003;98: 2751-6.
97. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005;49:329-36.
98. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011;7:e1002147.
99. Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002;21:4801-11.
100. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201.
101. Lee SK, Kim MH, Cheong JY, Cho SW, Yang SJ, Kwack K. Integrin alpha V polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver Int 2009;29:187-95.
102. Lees C, Howie S, Sartor RB, Satsangi J. The hedgehog signaling pathway in the gastrointestinal track : implications for development, homeostasis, and disease. Gastroenterology 2005;129:1696-710.
103. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005a;102:2992-7.
104. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005b; 102:17717-22.
105. Li Z, Dranoff JA, Chan EP, Uemura M, Sevigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007;46:1246-56.
106. Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm 2012;2012: 949157.
107. Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S et al. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 2006;80:6072-83.
108. Liu C, Billadeau DD, Abdelhakim H, Leof E, Kaibuchi K, Bernabeu C et al. IQGAP1 suppresses TβRIImediated myofibroblastic activation and metastatic growth in liver. J Clin Invest 2013;123:1138-56.
109. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
110. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006;103: 6001-6.
111. Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010;8:891-8.
112. Lu W, Lo SY, Chen M, Wu Kj, Fung YK, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology 1999;264:134-41.
113. Machida K, Liu JC, McNamara G, Levine A, Duan L, Lai MM. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol 2009;83:12590-600.
114. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001;75:1401-7.
115. Malaguarnera M, Di Fazio I, Ferlito L, Pistone G, Laurino A, Vinci E et al. Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000;12:937-9.
116. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou Ay et al. The epithelial-messenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
117. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007;46:48-57.
118. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, Kato N et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 2008;42:839-43.
119. Mazumdar B, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 2011;54:1149-56.
120. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray R. et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86: 2221-8.
121. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray R. et al. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 2013;87:7902-10.
122. Mazzocca A, Carloni V, Sciammetta S, Cordella C, Pantaleo P, Caldini A et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol 2002;37:322-30.
123. Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 2005;280:11329-39.
124. Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLOS One 2011;6:e23699.
125. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-72.
126. Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 2010;45:195-203.
127. Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol 2002;23:61-4.
128. Moradpour D, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996;222:51-63.
129. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63.
130. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127:S87-96.
131. Mukherjee A, Shrivastava S, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol 2014;88:7929-40.
132. Munakata T, Nakamura M, Liang Y, Li K, Lemon SM. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNAdependent RNA polymerase. Proc Natl Acad Sci USA 2005;102:18159-64.
133. Munakata T, Liang Y, Kim S, McGivern DR, Huibregtse J, Nomoto A et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 2007;3:1335-47.
134. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012;19(Suppl 1):42-7.
135. Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 2013;369:243-62.
136. Nishio T, Iimuro Y, Nitta T, Harada N, Yoshida M, Hirose T et al. Increased expression of collagenase in the liver induces hepatocyte proliferation with cytoplasmic accumulation of beta-catenin in the rat. J Hepatol 2003;38:468-75.
137. Nitta T, Kim JS, Mohuczy D, Behrns KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008;48:909-19.
138. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S206-14.
139. Obokata H, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H et al. Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature 2014a;505:641-7.
140. Obokata H, Sasai Y, Niwa H, Kadota M, Andrabi M, Takata N et al. Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature 2014b;505:676-80.
141. Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology 2010;51:1712-23.
142. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008;118:3331-42.
143. Ortiz V, Berenquer M, Rayon JM, Carrasco D, Berenquer J. Contribution of obesity to hepatitis Crelated fibrosis progression. Am J Gastroenterol 2002; 97:2408-14.
144. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 2014;59:2140-51.
145. Pangburn MK, Ferreira VP, Cortes C. Discrimination between host and pathogens by the complement system. Vaccine 2008;26(Suppl 8):I15-21.
146. Paradis V, Zalinski S, Chelbi E, Guedi N, Degos F, Vilgrain V et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
147. Park CY, Choi SH, Kang SM, Kang JI, Ahn BY, Kim H et al. Nonstructural 5A protein activates betacatenin signaling cascades : implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009;51: 853-64.
148. Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010;285:20870-81.
149. Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One 2011;6:e23943.
150. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014;108C:181-91.
151. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 2014;33:2826-35.
152. Ray R. Progress toward development of a hepatitis C vaccine with broad shoulders. Sci Transl Med 2011;3: 94ps33.
153. Ray R., Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997;272:10983-6.
154. Ray R., Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNFalpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998;273:2256-9.
155. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010;202:862-6.
156. Raychoudhury A, Shrivastava S, Steele R, Dash S, Kanda T, Ray R et al. Hepatitis C virus infection impairs IRF-7 translocation and alpha interferon synthesis in immortalized human hepatocytes. J Virol 2010; 84:10991-8.
157. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011;85:12881-9.
158. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-73.
159. Roberts AP, Lewis AP, Jopling CL. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 2011;102:101-39.
160. Roingeard P. Hepatitis C virus diversity and hepatic steatosis. J Viral Hepat 2013;20:77-84.
161. Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E et al. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 2006;80:2832-41.
162. Saito K, Meyer K, Warner R, Basu A, Ray R., Ray R. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006;80:4372-9.
163. Saito K, Ait-Goughoulte M, Truscott SM, Meyer K, Blazevic A, Abate G et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 2008;82:3320-8.
164. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virunonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995;69:3893-6.
165. Scarselli E, Ansuini H, Cerino R, Roccasecca M, Acali S, Filocamo G et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-25.
166. Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M et al. Hepatitis C virusreplicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005;129:246-58.
167. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006;387:349-60.
168. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008;47:2127-33.
169. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance and diagnosis. Semin Liver Dis 2010;30: 3-16.
170. Shin JY, Hur W, Wang JS, Jang JW, Kim CW, Bae SH et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med 2005;37:138-45.
171. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
172. Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology 2011;53:406-14.
173. Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1ß/IL-18 in circulatory and resident liver marcrophages. J Virol 2013a;87: 12284-90.
174. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013b;5:479-86.
175. Shrivastava S, Ray RB. Hepatitis C virus infection, autophagy and innate immune response. In: Hayat MA (ed): Autophagy. Cancer, other pathologies, inflammation, immunity, infection and aging, Vol. 3 (pp 164-90). Amsterdam: Academic Press, Elsevier, 2014.
176. Sir D, Chen WL, Choi J, Wakita T, Yen TS, Ou JH. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. Hepatology 2008;48:1054-61
177. Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L et al. Hedgehog-mediated epithelial-tomesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009; 137:1478-88.
178. Tang Y, Kitjsin K, Jogunoori W, Li C, Deng CX, Muller SC et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 2008;19:2445-50.
179. Tanida I, Fukasawa M, Ueno T, Kominami E, Wakita T, Hanada K. Knockdown of autophagy-related gene decreases the production of infectious hepatitis C virus particles. Autophagy 2009;5:937-45.
180. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y et al. Hepatitis C virus core protein upregulates transforming growth factor-beta1 transcription. J Med Virol 2004;72:52-9.
181. Tanji Y, Hijikata M, Hirowatari Y, Shimotohno K. Hepatitis C virus polyprotein processing : kinetics and mutagenic analysis of serine proteinase-dependent cleavage. J Virol 1994;68:8418-22.
182. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008;135:1729-38.
183. Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82-8.
184. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
185. Todorovic V, Rifkin DB. LTBPs, more than just an escort service. J Cell Biochem 2012;113:410-8.
186. Torre D, Zeroli C, Giola M, Ferrario G, Fiori GP, Bonetta G et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994;18:194-8.
187. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009;28:4022-33.
188. Veerapu NS, Park SH, Tully DC, Allen TM, Rehermann B. Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 2014;124:3469-78.
189. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132:667-78.
190. Wang QM, Hockman MA, Staschke K, Johnson RB, Case KA, Lu J et al. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNAdependent RNA polymerase. J Virol 2002;76:3865-72.
191. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology 2008;47:1394-400.
192. Williams P, Chaudhry Y, Goodfellow IG, Bilington J, Powell R, Spiller OB et al. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7A. J Biol Chem 2003;278:10691-6.
193. Wilson GK, Brimacombe CL, Rowe IA, Reynolds GM, Fletcher NF, Stamataki Z et al. A dual role for hypoxia inducible factor-1α in the hepatitis C virus life cycle and hepatoma migration. J Hepatol 2012; 56:803-9.
194. Wu Y, Zuo J, Ji G, Saiyin H, Liu X, Yin F et al. Proapoptotic function of integrin beta(3) in human hepatocellular carcinoma cells. Clin Cancer Res 2009; 15:60-9.
195. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33.
196. Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Res 2012;72:4047-59.
197. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP et al. A paracrine requirement for hedgehog signaling in cancer. Nature 2008;455:406-10.
198. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5:1207-1213.e2.
199. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-47.
200. Zekri AR, Bahnassy AA, Abdel-Wahab SA, Khafagy MM, Loutfy SA, Radwan H et al. Expression of proand anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. J Gastroenterol Hepatol 2009;24:416-28.
201. Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 2002;95:896-906.
202. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012;56: 769-75.
203. Zhou X, Jamil A, Nash A, Chan J, Trim N, Iredale JP et al. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis. J Biol Chem 2006;281: 39757-65.
204. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol 2012;3:56.